The serum gamma glutamyl transpeptidase - A non invasive diagnostic bio marker of chronic anicteric non alcoholic liver diseases

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 4, 2013, Pages 691-694

  Krishnamurthy, H A ^a  

^a Department of General Medicine   (India)

Author keywords

Fatty liver; Hepatitis; Serum GGT; Ultrasound abdomen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CHRONIC ANICTERIC NON ALCOHOLIC LIVER DISEASE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER FUNCTION TEST; MALE; NON INVASIVE MEASUREMENT; OBESITY; SENSITIVITY ANALYSIS;

EID: 84875898493     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/5569.2883     Document Type: Article

References (30)

1. Jules L dienstag, Chronic Hepatitis. In Longo, Fauci, Kasper, Hauser, et al., editors; Harrisońs Principles of Internal Medicine, 18th Edition, United States of America, McGraw Hill Companies. 2012: 2567; 3588-90.
2. Laker MF. Liver Function Tests. Br Med J. 1990; 301: 250-51.
3. Rosalki SB. Gamma-glutamyl transpeptidase. In: Bodanski O, Latner AL, eds Advances in clinical chemistry. Vol. 17. NewYork, London: Academic Press. 1975; 53-107.
4. [4] Burt Ad, Day CP Pathophysiology of the Liver. In: Nacsween RNM, Burt AD, Portmann BC, Ishak KG, Schever PJ, Anthony PP eds. Pathology of the liver. 4th edition. Edinburg: Churchill Livingstone. 2002; 67-105.
5. Penn R, Worthington DJ Is serum y-glutamyl transferase a misleading test. Br Med J. 1983; 286: 531-35.
6. Rosalki SB Gamma-glutamyltranspeptidase. Advclin Chem. 1975; 17: 53-107.
7. Percy-Robb IW, Finlayson NDC.Clinical chemistry of liver disease. In: Shearman JC. Finlayson NDC Camilleri M, eds. Diseases of the gastrointestinal tract and liver. 3rd edition, London: Churchill Livingstone. 1977;735-61.
8. Goldberg DM, Martin JV. Role of y_glutamyl transpeptidase activity in the diagnosis of hepatobiliary disease. Digestion.1975; 12:232-46.
9. Zhang Ju-Bo, Chen Yi, Zhang Boheng, Xie Xiaoying, Zhang Lan, Ge Ninling, et al, Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization; European Journal of Gastroenterology and Hepatology. 2011 Sep; 23 (9): 787-93.
10. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357: 1069-75.
11. Hui AY, Chan HLY, Wong VWS, Liew CT, Chim AML, Chan FKL, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005; 100: 616-23.
12. Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. Crit Rev Clin Lab Sci. 1980; 12 (1): 1-58.
13. Meister A. The gamma-glutamyl cycle. Diseases associated with specific enzyme deficiencies. Ann. Intern. Med. 1974 August; 81 (2): 247-53.
14. Rosalki SB, Tarlow D, Rau D. Plasma gamma-glutamyltranspeptidase elevation in patients receiving enzyme-inducing drugs. Lancet. 1971 August; 2 (7720): 376-77.
15. th Edition; United States of America, McGraw Hill companies. 2012; 2603-05.
16. Mottin, CC, Moretto, M, Padoin, AV et al., The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes. Surg 2004;14: 635-37.
17. Executive Summary of The Third Report of National Cholesterol Education Program (NCEP), Report Panel on Detection, Evaluation And Treament of High Blood Cholesterol In Adults (Adult Treatment Panel- III), JAMA. 2001;285:2486-97.
18. RAICHEM, Division of hemagen diagnostics, Inc. San Diego; CA 92:111-1203.
19. M Irie, T Sohda, K Iwata, H Kunimoto, A Fukunaga, S Kuno et al. Levels of The Oxidative Stress Marker Gamma Glutamyltranspeptidase at Different Stages of Nonalcoholic Fatty Liver Disease. The Journal of International Medical Research. 2012;40:924-33.
20. Barouki R, Chobert MN, Finidori J, Aggerbeck M, Nalpas B, Hanoune J Ethanol effects in a rat hepatoma cell line: induction of gamma-glutamyltransferase. Hepatology. 1983;3 (3): 323-29.
21. Angulo, P, Keach, JC, Batts, KP, Lindor, KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30:1356-62.
22. Jeanne M Clark, Frederick L Brancati, Anna Mae Diehl, Nonalcoholic Fatty Liver Disease; Gastroenterology. 2002;122:1649-57.
23. Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR Jr. A strong interaction between serum gamma-glutamyl transferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clinical Chemistry. 2007; 53 (6): 1092-98.
24. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis. B. J Hepatol. 2003; 39: 222-30.
25. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E, et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of northern Italian patients. Liver. 1999; 19: 432-37.
26. Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti Set al.Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012 Apr; 32(4):629-34.
27. Christi A.Matteoni, Zobair M. Younossi, Navdeep Boparai, Yao Chang Liu, Arthur J. McCullough. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. June 1999; 116(6): 1413-19.
28. Giovanni Targher, Lorenzo Bertolini, Felice Poli, Stefano Rodella, Luca Scala, Roberto Tessar et al. Nonalcoholic Fatty Liver Disease and Risk of FutureCardiovascular Events Among Type 2 Diabetic Patients. American Diabetes Association. 2005 December; Diabetes vol. 54.
29. Mark E. Malliard, Michael F. Sorrell, Alcoholic Liver Disease, In Longo, Fauci, Kasper, Hauser, Jameson, Loscalzo editors. Harrisońs Principles of Internal Medicine. 18th Edition; United States of America; McGraw Hill companies. 2012; 2589-90.
30. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med. 2004;141:946-56.